Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2022-04-26 Regulatory Filings
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a detailed response letter from Shuttle Pharmaceuticals Holdings, Inc. to the U.S. Securities and Exchange Commission (SEC) regarding comments on their Draft Registration Statement on Form S-1. It addresses specific SEC comments on financial disclosures, accounting policies, clinical trial descriptions, and regulatory compliance related to the registration statement. The document references the Form S-1 registration process, amendments, and detailed financial and operational disclosures typical of a registration statement filing. This is not an annual report, earnings release, or other types of filings but a regulatory correspondence related to a securities registration. Therefore, the document fits best under Regulatory Filings (RNS), which covers general regulatory announcements, compliance documents, and miscellaneous filings that do not fit other categories.
2022-04-26 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a confidential draft registration statement on Form S-1 filed with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It is a preliminary prospectus for an initial public offering (IPO) of common stock. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, management discussion, and other typical sections of a registration statement/prospectus. This type of document is related to capital raising and financing activities, specifically an IPO registration statement under the Securities Act of 1933. It is not an annual report, earnings release, or any other financial report type. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2022-04-26 English
Regulatory Filings 2022
Regulatory Filings
2022-03-18 English
Regulatory Filings 2022
Regulatory Filings
2022-02-22 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is a confidentially submitted Registration Statement on Form S-1 to the SEC by Shuttle Pharmaceuticals Holdings, Inc. It includes detailed exhibits such as underwriting agreements, amended certificates, employment agreements, contracts, and consents. The Form S-1 is a registration statement used for securities offerings under the Securities Act of 1933, indicating it is related to capital raising activities. The document is not an annual report, earnings release, or any other financial report but a regulatory filing for securities registration. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is not a mere announcement but the actual filing. Confidence is high due to explicit Form S-1 identification and detailed exhibit list.
2022-02-11 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed confidentially with the SEC by Shuttle Pharmaceuticals Holdings, Inc. It includes exhibits such as underwriting agreements, amended certificates of incorporation, employment agreements, and other legal and corporate governance documents. The Form S-1 is a registration statement used for securities offerings under the Securities Act of 1933, indicating a capital raising event. The document is not an annual report, earnings release, or any other financial report but rather a regulatory filing related to a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a full filing, not just an announcement or certification.
2022-02-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.